Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)

3 Months Ended

Mar. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value

The following table presents the changes in the development derivative liability for the three months ended March 31, 2022 and 2021:

		Three months ended March 31,
	Fair Value Hierarchy Level	2022		2021
Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively	3	$	27,726	$	—
Non-cash research and development expense		4,951		2,248
Cash receipts from SFJ		750		750
Change in the fair value of development derivative liability		(33,427)		1,599
Fair value at end of period	3	$	—	$	4,597